{"id":20214,"date":"2018-07-11T01:00:00","date_gmt":"2018-08-08T01:17:25","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/08\/08\/%e6%96%b0%e4%b8%80%e4%bb%a3%e7%9a%84%e7%bd%97%e6%b0%8f%ef%bc%9a%e6%95%b0%e6%8d%ae%e5%88%86%e6%9e%90%e5%a6%82%e4%bd%95%e8%ae%a9%e5%ae%83%e4%bf%9d%e6%8c%81%e8%82%bf%e7%98%a4%e9%a2%86%e5%9f%9f%e7%9a%84\/"},"modified":"2018-08-08T09:17:26","modified_gmt":"2018-08-08T01:17:26","slug":"%e6%96%b0%e4%b8%80%e4%bb%a3%e7%9a%84%e7%bd%97%e6%b0%8f%ef%bc%9a%e6%95%b0%e6%8d%ae%e5%88%86%e6%9e%90%e5%a6%82%e4%bd%95%e8%ae%a9%e5%ae%83%e4%bf%9d%e6%8c%81%e8%82%bf%e7%98%a4%e9%a2%86%e5%9f%9f%e7%9a%84","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/20214\/","title":{"rendered":"\u65b0\u4e00\u4ee3\u7684\u7f57\u6c0f\uff1a\u6570\u636e\u5206\u6790\u5982\u4f55\u8ba9\u5b83\u4fdd\u6301\u80bf\u7624\u9886\u57df\u7684\u9886\u5148\u5730\u4f4d"},"content":{"rendered":"
\n

\u6982\u89c8<\/span><\/strong><\/span><\/h4>\n

Roche<\/span>\u5728\u672c\u5c4a<\/span>ASCO<\/span>\u4e0a\u91cd\u70b9\u9610\u8ff0\u4e86\u81ea\u5df1\u7684\u6570\u5b57\u5316\u4e0e\u4e2a\u6027\u5316\u5065\u5eb7\u6218\u7565\uff0c\u5e76\u4e3e\u4f8b\u8bf4\u660e\u4e86\u65b0\u7684\u6218\u7565\u5982\u4f55\u8ba9\u81ea\u5df1\u4fdd\u6301\u5728\u80bf\u7624\u9886\u57df\u7684\u9886\u5148\u5730\u4f4d\u3002<\/span><\/span><\/p>\n

<\/span><\/p>\n

\n

Roche<\/span>\u5360\u636e\u80bf\u7624\u9886\u57df\u7684\u9738\u4e3b\u5730\u4f4d\u5df2\u7ecf\u6709\u4e00\u6bb5\u65f6\u95f4\uff0c\u4f46\u662f\u5728\u6700\u65b0\u7684\u80bf\u7624\u514d\u75ab\u6d6a\u6f6e\u4e2d\u7a0d\u663e\u843d\u540e\u3002\u4e0d\u8fc7\uff0c<\/span>Roche<\/span>\u73b0\u5728\u5728\u6570\u5b57\u5316\u4e0e\u4e2a\u6027\u5316\u533b\u7597\uff08<\/span>digital and personalizedhealthcare<\/span>\uff09\u4e2d\u5927\u91cf\u6295\u8d44\uff0c\u5b83\u671f\u5f85\u4ee5\u6b64\u786e\u7acb\u5c06\u6765\u81ea\u5df1\u5728\u80bf\u7624\u9886\u57df\u7684\u5730\u4f4d\u3002<\/span>
<\/span><\/p>\n

Roche<\/span>\u5728\u521a\u521a\u8fc7\u53bb\u7684<\/span>ASCO<\/span>\u5927\u4f1a\u4e0a\u56de\u987e\u4e86\u81ea\u5df1\u80bf\u7624\u7ba1\u7ebf\u7684\u4e00\u4e9b\u6570\u636e\uff0c\u5411\u4e1a\u754c\u9610\u8ff0\u4e86\u81ea\u5df1\u5982\u4f55\u5c06\u4e34\u5e8a\u8bd5\u9a8c\u4e0e\u57fa\u56e0\u6d4b\u5e8f\u7ed3\u5408\uff0c\u4ee5\u671f\u53d1\u73b0\u80ba\u764c\u9886\u57df\u7684\u673a\u4f1a\u3002\uff08\u8bf7\u67e5\u770b<\/span>“<\/span><\/span>Roche,Bristol On The Defensive After Merck’s Lung Cancer Wins At ASCO<\/span>“- Scrip, 6 Jun, 2018.<\/span>\uff09<\/span><\/span><\/p>\n

\u4f46\u662f\u7f57\u6c0f\u7684\u8ba8\u8bba\u5e76\u6ca1\u6709\u8fc7\u591a\u805a\u7126\u5728\u5982\u4f55\u901a\u8fc7\u65b0\u836f\u6216\u8005\u8001\u836f\u6269\u5c55\u9002\u5e94\u75c7\u7b49\u65b9\u6cd5\u7ef4\u6301\u5173\u952e\u7684\u80bf\u7624\u5e02\u573a\uff0c\u76f8\u53cd\uff0c\u5b83\u5c06\u8ba8\u8bba\u805a\u7126\u5728\u4e86\u751f\u7269\u6807\u8bb0\u7269\uff08<\/span>biomarkers<\/span>\uff09\u4e0e\u6570\u5b57\u5316\u5065\u5eb7\u5de5\u5177\u3002<\/span><\/span><\/p>\n

\u8fd9\u4e9b\u65b9\u5411\u5bf9<\/span>Roche<\/span>\u800c\u8a00\u5176\u5b9e\u5e76\u4e0d\u7b97\u592a\u65b0\u9c9c\u7684\u8bdd\u9898\uff0c\u4f46\u662f\u4eca\u5e74\u5b83\u7ed9\u51fa\u4e86\u5927\u6570\u636e\uff08<\/span>big data<\/span>\uff09\u9886\u57df\u7684\u6295\u8d44\u662f\u5982\u4f55\u5e2e\u52a9\u5b83\u63a8\u8fdb\u7814\u53d1\u3001\u83b7\u5f97\u66f4\u597d\u56de\u62a5\u7684\u5177\u4f53\u6848\u4f8b\uff01<\/span><\/span><\/p>\n

\u7f57\u6c0f\u5236\u836f\u7684<\/span>CEO Daniel O\u2019Day<\/span>\u63d0\u5230\u5229\u7528\u5355\u4e00\u7684\u75be\u75c5\u6807\u8bb0\u7269\uff0c\u4e00\u4e2a\u91cd\u78c5\u836f\u7269\u6253\u904d\u5929\u4e0b\u7684\u65f6\u4ee3\u5df2\u7ecf\u8fc7\u53bb\uff0c\u73b0\u5728\u884c\u4e1a\u8f6c\u5411\u4e2a\u6027\u5316\u6cbb\u7597\uff0c\u7ed3\u5408\u65b0\u4e00\u4ee3\u7684\u57fa\u56e0\u6d4b\u5e8f\u4e0e\u6cbb\u7597\u53cd\u5e94\u76d1\u6d4b\u6280\u672f\uff0c\u901a\u8fc7\u9776\u5411\u836f\u7269\u4e0e\u514d\u75ab\u6cbb\u7597\u8054\u7528\uff0c\u7cbe\u51c6\u6cbb\u7597\u6bcf\u4e2a\u60a3\u8005\u2014\u2014\u8fd9\u4e00\u5207\u5bfc\u81f4\u5bf9\u6570\u636e\u5904\u7406\u80fd\u529b\u7684\u9700\u6c42\u65e5\u76ca\u63d0\u9ad8\u3002<\/span><\/span><\/p>\n

\u8fd9\u5c31\u662f<\/span>Roche<\/span>\u52aa\u529b\u5efa\u7acb\u81ea\u5df1\u201c\u5728\u672a\u6765\u7684\u5dee\u5f02\u5316\u7ade\u4e89\u4f18\u52bf\u7684\u57fa\u7840\u201d<\/span>\uff0c\u4e3b\u8981\u662f\u5229\u7528\u5b83\u5728\u8bca\u65ad\u9886\u57df\u7684\u4f18\u52bf\uff0c\u63a8\u52a8\u9776\u5411\u6cbb\u7597\u4e0e\u4f34\u968f\u8bca\u65ad\u7684\u7ed3\u5408\u3002<\/span><\/span><\/p>\n

\u6570\u5b57\u5316\u7684\u5174\u8d77\u6df1\u523b\u5f71\u54cd\u7740\u6574\u4e2a\u5065\u5eb7\u62a4\u7406\u4f53\u7cfb\uff0c<\/span>Roche<\/span>\u5e0c\u671b\u81ea\u5df1\u8d70\u5728\u524d\u5217\uff0c\u5e76\u4e14\u5df2\u7ecf\u5728\u91c7\u53d6\u884c\u52a8\u3002<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u8bf4\uff1a\u201c\u6211\u8ba4\u4e3a\u6211\u4eec\u5c06\u4f1a\u63d0\u5347\u80bf\u7624\u6cbb\u7597\u7684\u6574\u4e2a\u751f\u6001\u4f53\u7cfb\uff0c\u4f46\u8fd9\u4e2a\u8fc7\u7a0b\u9700\u8981\u5168\u4f53\u516c\u53f8\u7684\u5171\u540c\u52aa\u529b\uff0c\u56e0\u4e3a\u5f53\u4f60\u9700\u8981\u6539\u53d8\u884c\u4e1a\u6807\u51c6\u65f6\uff0c\u9700\u8981\u5168\u884c\u4e1a\u7684\u5171\u540c\u52aa\u529b\u3002\u6574\u4e2a\u884c\u4e1a\u90fd\u5728\u63d0\u5347\uff0c\u4f46\u6211\u76f8\u4fe1\u6211\u4eec\u516c\u53f8\u5c06\u4f1a\u5177\u6709\u660e\u663e\u7684\u4f18\u52bf\uff0c\u56e0\u4e3a\u6211\u4eec\u662f\u8fd9\u4e2a\u9886\u57df\u7684\u5148\u884c\u8005\u3002\u6211\u4eec\u5c06\u575a\u6301\u6211\u4eec\u7684\u6574\u4f53\u6218\u7565\u3002\u201d<\/span><\/span><\/p>\n

\u7f57\u6c0f\u76ee\u524d\u662f\u80bf\u7624\u9886\u57df\u7684\u9886\u5bfc\u8005\uff0c\u5bf9\u6b64<\/span>O\u2019Day<\/span>\u8fdb\u4e00\u6b65\u8868\u793a\uff1a\u201c\u6211\u4eec\u5728\u4e0b\u4e00\u4ee3\u7684\u4e2a\u4f53\u5316\u5065\u5eb7\u62a4\u7406\u4e2d\u4e5f\u5c06\u4f1a\u6210\u4e3a\u9886\u5bfc\u8005\uff0c\u4e0b\u4e00\u4ee3\u5065\u5eb7\u62a4\u7406\u5c06\u5168\u9762\u62e5\u62b1\u57fa\u56e0\u6280\u672f\u4e0e\u771f\u5b9e\u4e16\u754c\u6570\u636e\uff08<\/span>Real-word data<\/span>\uff09\uff0c\u76ee\u524d\u884c\u4e1a\u5df2\u7ecf\u5904\u4e8e\u5173\u952e\u7684\u5341\u5b57\u8def\u53e3\uff0c\u6211\u76f8\u4fe1\u6211\u4eec\u5728\u80bf\u7624\u9886\u57df\u5c06\u4f1a\u5177\u6709\u72ec\u7279\u7684\u7ade\u4e89\u4f18\u52bf\u3002\u201d<\/span><\/span><\/p>\n

\u5efa\u7acb\u80fd\u529b<\/span><\/strong><\/span><\/h2>\n

Roche<\/span>\u957f\u671f\u5229\u7528\u81ea\u5df1\u7684\u8bca\u65ad\u4e1a\u52a1\u7684\u4f18\u52bf\uff0c\u4e8b\u5b9e\u4e0a\u5b83\u5728\u751f\u7269\u6807\u8bb0\u7269\u4e0e\u4f34\u968f\u8bca\u65ad\u65b9\u9762\u7684\u4f18\u52bf\u4e5f\u652f\u6301\u4e86\u5b83\u7684\u80bf\u7624\u4e1a\u52a1\u7684\u6210\u529f\u3002\u4e0e\u6b64\u540c\u65f6\uff0c\u8be5\u516c\u53f8\u4e5f\u957f\u671f\u5173\u6ce8\u4e8e\u4e0e\u65b0\u6280\u672f\u516c\u53f8\u5efa\u7acb\u4f19\u4f34\u5173\u7cfb\uff0c\u6bd4\u5982<\/span>Foundation Medicine Inc.<\/span> <\/span>\u548c<\/span> <\/span><\/span>Flatiron Health Inc.<\/span>. (<\/span>\u8bf7\u67e5\u770b<\/span>“<\/span><\/span>Roche Could Repeat Genentech Success With Foundation MedicinePartnership<\/span>” – Pink Sheet, 12 Jan, 2015.)<\/span><\/p>\n

\u5728\u4eca\u5e74<\/span>2<\/span>\u6708\uff0c\u7f57\u6c0f\u65a5\u8d44<\/span>19<\/span>\u4ebf\u7f8e\u5143\uff0c\u6536\u8d2d\u4e86<\/span>Flatiron Health<\/span>\u7684\u5269\u4f59\u80a1\u4efd\uff0c\u4ece\u800c\u5b8c\u5168\u63a7\u80a1\u4e86\u8fd9\u5bb6\u57fa\u4e8e\u4e91\u8ba1\u7b97\u6280\u672f\u7684\u80bf\u7624\u5206\u6790\u516c\u53f8\u3002\uff08\u8bf7\u67e5\u770b<\/span>“<\/span><\/span>Roche ToBuild RWE Cancer Data Extraction Role With Flatiron Buy<\/span>“- Scrip, 19 Feb, 2018.<\/span>\uff09<\/span>Roche<\/span>\u8ba1\u5212\u8ba9<\/span>Flatiron Health<\/span>\u7ee7\u7eed\u72ec\u7acb\u8fd0\u8425\uff0c\u5e76\u8ba9\u5b83\u7ee7\u7eed\u4e0e\u5916\u90e8\u5176\u4ed6\u751f\u7269\u5236\u836f\u516c\u53f8\u5408\u4f5c\u3002<\/span><\/span><\/p>\n

Roche<\/span>\u6b64\u524d\u5df2\u7ecf\u4e0e<\/span>Flatiron<\/span>\u5408\u4f5c\uff0c\u751f\u6210\u771f\u5b9e\u4e16\u754c\u8bc1\u636e\uff08<\/span>real-world evidence (RWE)<\/span>\uff09\uff0c\u63a2\u7d22\u6316\u6398\u7535\u5b50\u533b\u7597\u6570\u636e\u7684\u53ef\u884c\u6027\uff0c\u5bfb\u6c42\u5229\u7528<\/span>RWE<\/span>\u5e2e\u52a9\u533b\u4fdd\u6d41\u7a0b\u3001\u63a8\u52a8\u836f\u7269\u5f00\u53d1\u3001\u652f\u6301\u6cd5\u89c4\u6ce8\u518c\u3002\uff08\u8bf7\u67e5\u770b<\/span>“<\/span><\/span>Roche’s Guide To Success In Oncology<\/span>“- Pink Sheet, 27 Jun, 2016.<\/span>\uff09<\/span><\/span><\/p>\n

Roche<\/span>\u5728\u672c\u6b21<\/span>ASCO<\/span>\u4e0a\u5c55\u793a\u4e86\u6700\u65b0\u7684\u4e00\u4e9b\u8fdb\u5c55\u3002<\/span><\/span><\/p>\n

\u6da6\u6ed1\u533b\u4fdd\u8fdb\u5c55<\/span><\/strong><\/span><\/h2>\n

\u5230\u76ee\u524d\u4e3a\u6b62\uff0c<\/span>RWE<\/span>\u4e3b\u8981\u7528\u4e8e\u533b\u4fdd\u65b9\u9762\uff0c\u4e3b\u8981\u7528\u4e8e\u5411\u4ed8\u6b3e\u65b9\u8bc1\u660e\u836f\u7269\u5728\u4e34\u5e8a\u8bd5\u9a8c\u8bbe\u8ba1\u4e4b\u5916\u7684\u76ca\u5904\u3002\u6536\u96c6\u5927\u91cf\u53ef\u9760\u7684\u6570\u636e\u80fd\u591f\u652f\u6301\u57fa\u4e8e\u4ef7\u503c\u7684\u62a5\u9500\uff08<\/span>value-basedreimbursement<\/span>\uff09\uff0c\u56e0\u4e3a\u57fa\u4e8e\u4ef7\u503c\u7684\u62a5\u9500\u4e0e\u4ea7\u751f\u7684\u6210\u679c\u76f4\u63a5\u6302\u94a9\u3002<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u8bf4\uff1a\u201c\u5982\u679c\u6211\u4eec\u62e5\u6709\u5927\u91cf\u53ef\u9760\u7684\u6570\u636e\u6e90\uff0c\u90a3\u4e48\u6211\u4eec\u5c31\u80fd\u591f\u652f\u6301\u57fa\u4e8e\u4ef7\u503c\u7684\u5b9a\u4ef7\u4ee5\u53ca\u76f8\u5173\u7684\u65b0\u578b\u7684\u62a5\u9500\u4f53\u7cfb\u3002\u201d<\/span><\/span><\/p>\n

\u4ed6\u4e3e\u4f8b\u8bf4\u660e\u6570\u636e\u5206\u6790\u6280\u672f\u5bf9\u62a5\u9500\u7684\u5f71\u54cd\uff0c\u4ee5\u6b64\u8bc1\u660e\u201c\u8fd9\u4e0d\u662f\u7eaf\u7cb9\u7684\u7406\u8bba\u7684\u4e1c\u897f\uff0c\u800c\u662f\u786e\u786e\u5b9e\u5b9e\u5728\u63a8\u52a8\u6211\u4eec\u7684\u4e1a\u52a1\uff0c\u8ba9\u60a3\u8005\u66f4\u5feb\u901f\u7684\u7528\u4e0a\u6211\u4eec\u7684\u836f\u7269\uff0c\u6700\u7ec8\u63a8\u52a8\u6211\u4eec\u4e1a\u52a1\u7684\u589e\u957f\u3002\u201d<\/span><\/p>\n

Roche<\/span>\u7528\u5b83\u7684\u7b2c\u4e8c\u4ee3<\/span>ALK<\/span>\u6291\u5236\u5242<\/span>Alecensa<\/span><\/em> (alectinib)<\/span>\u6765\u4e3e\u4f8b\uff0c\u8fd9\u662f\u5b83\u7684\u4e00\u6b3e\u80ba\u764c\u836f\u7269\u3002<\/span>O\u2019Day<\/span>\u5f3a\u8c03\u8fd9\u6b3e\u9776\u5411\u836f\u8fc5\u901f\u901a\u8fc7\u4e86\u5f00\u53d1\u9636\u6bb5\uff0c\u56e0\u6b64\u5728\u4e0e\u652f\u4ed8\u65b9\u8fdb\u884c\u533b\u4fdd\u8c08\u5224\u65f6\u8fd8\u6ca1\u6709\u5b8c\u5168\u7684\u6570\u636e\u2014\u2014\u5728\u8fd9\u79cd\u60c5\u51b5\u4e0b\uff0c<\/span>Flatiron<\/span>\u7684\u6570\u636e\u5e93\u88ab\u7528\u505a\u63a7\u5236\u81c2\uff08<\/span>control arms<\/span>\uff09\uff0c\u7528\u4e8e\u6a21\u62df\u5168\u7403\u4e0d\u540c\u5e02\u573a\u7684\u6807\u51c6\u7597\u6cd5\u3002<\/span><\/span><\/p>\n

\u4ed6\u63d0\u5230\uff1a\u201c\u901a\u8fc7\u8fd9\u4e2a\u65b9\u6cd5\uff0c\u6211\u4eec\u5728\u5168\u7403\u8fd1<\/span>20<\/span>\u4e2a\u56fd\u5bb6\u7684\u83b7\u6279\u901f\u5ea6\u5e73\u5747\u4e0b\u6765\u6bd4\u4f20\u7edf\u7684\u533b\u4fdd\u6d41\u7a0b\u5feb\u4e86\u8fd1<\/span>1<\/span>\u5e74\uff01\u201d<\/span><\/span><\/p>\n

Flatiron<\/span>\u7684\u6570\u636e\u4e5f\u88ab\u7528\u6765\u5e2e\u52a9<\/span>Roche<\/span>\u7684<\/span>PD-L1<\/span>\u836f\u7269<\/span>Tecentriq<\/span><\/em>(atezolizumab)<\/span>\u8fdb\u5165\u82f1\u56fd\u7684<\/span>NICE<\/span>\u7684\u62a5\u9500\u8303\u56f4\uff0c<\/span>NICE<\/span>\u901a\u5e38\u8981\u6c42\u6709<\/span>5<\/span>\u5e74\u7684\u76f8\u5173\u6570\u636e\u3002<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u8bf4\uff1a\u201c\u901a\u8fc7\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u6211\u4eec\u83b7\u5f97\u4e86<\/span>2.5<\/span>\u5e74\u7684\u6570\u636e\uff0c\u6211\u4eec\u5229\u7528<\/span>Flatiron<\/span>\u7684\u6570\u636e\u5e93\u6a21\u62df\u4e86<\/span>5<\/span>\u5e74\u7684\u6570\u636e\u3002\u201d\u57fa\u4e8e<\/span>Flatiron<\/span>\u7684\u6570\u636e\uff0c<\/span>Tecentriq<\/span>\u6210\u4e3a\u4e86\u9996\u4e2a\u5728\u82f1\u56fd\u83b7\u6279\u7684\u80ba\u764c<\/span>2<\/span>\u7ebf\u80bf\u7624\u514d\u75ab\u7597\u6cd5\u3002<\/span>O\u2019Day<\/span>\u8865\u5145\u9053\uff1a\u201c<\/span>Flatiron<\/span>\u7684\u6570\u636e\u5e2e\u52a9<\/span>Roche<\/span>\u53d6\u5f97\u4e86\u66f4\u52a0\u9886\u5148\u7684\u4f4d\u7f6e\u3002\u201d<\/span><\/span><\/p>\n

\u9664\u4e86\u5e2e\u52a9\u5411\u652f\u4ed8\u65b9\u5c55\u793a\u4ef7\u503c\uff0c\u83b7\u5f97\u66f4\u597d\u7684\u62a5\u9500\u653f\u7b56\u4e4b\u5916\uff0c\u5168\u9762\u7684\u6570\u636e\u5206\u6790\u8fd8\u53ef\u4ee5\u901a\u8fc7\u534f\u52a9\u63d0\u4f9b\u5168\u9762\u7684\u8bca\u65ad\u3001\u4e2a\u6027\u5316\u7684\u6cbb\u7597\u65b9\u6848\u4e0e\u4e34\u5e8a\u6570\u636e\uff0c\u6765\u63d0\u5347\u4e2a\u6027\u5316\u7684\u533b\u7597\u670d\u52a1\u3002\u8fd9\u662f\u5e94\u7528\u4e0b\u4e00\u4ee3\u6d4b\u5e8f\u6280\u672f\uff08<\/span>next-generationsequencing\uff0cNGS<\/span>\uff09\u5b9e\u73b0\u7684\u3002<\/span><\/span><\/p>\n

\u52a0\u901f\u7814\u53d1<\/span><\/strong><\/span><\/h2>\n

Roche<\/span>\u76f8\u4fe1\u62e5\u62b1\u5927\u6570\u636e\u4e0e\u5206\u6790\u6280\u672f\u80fd\u591f\u6781\u5927\u63d0\u5347\u7814\u53d1\u7684\u6548\u7387\uff0c\u7814\u53d1\u51fa\u66f4\u591a\u5dee\u5f02\u5316\u7684\u4ea7\u54c1\uff0c\u964d\u4f4e\u7814\u53d1\u6210\u672c\uff0c\u52a0\u901f\u4e0a\u5e02\u8fdb\u7a0b\uff0c\u76ee\u6807\u7cbe\u51c6\u4ece\u800c\u66f4\u597d\u7684\u51c6\u5907\u7533\u62a5\u8d44\u6599\uff0c\u80fd\u7ed9\u60a3\u8005\u5e26\u6765\u66f4\u591a\u7684\u4ef7\u503c\u4ece\u800c\u4e5f\u7ed9\u81ea\u5df1\u5e26\u6765\u66f4\u591a\u7684\u56de\u62a5\u3002\u66f4\u52a0\u91cd\u8981\u7684\u662f\uff0c\u8fd9\u4e9b\u5de5\u5177\u80fd\u591f\u5e2e\u52a9\u516c\u53f8\u66f4\u6df1\u5ea6\u7684\u4e86\u89e3\u751f\u7269\u5b66\u673a\u7406\uff0c\u66f4\u597d\u7684\u9274\u522b\u9776\u70b9\uff0c\u63d0\u5347\u4e34\u5e8a\u8bbe\u8ba1\u4e0e\u62db\u52df\u7684\u6548\u7387\u3002<\/span><\/span><\/p>\n

\u9664\u4e86\u4e0e<\/span>Flatiron<\/span>\u7684\u5408\u4f5c\uff0c<\/span>Roche<\/span>\u8fd8\u4e0e\u8bca\u65ad\u516c\u53f8<\/span>FoundationMedicine<\/span>\u5728<\/span>NGS<\/span>\u4e0e\u590d\u6742\u8bca\u65ad\u5de5\u5177\u65b9\u9762\u6709\u5408\u4f5c\u3002\uff08\u8bf7\u67e5\u770b<\/span>“<\/span><\/span>Pharma trialneeds drive Roche’s $1.2bn Foundation Medicine deal <\/span>“- Scrip, 12 Jan, 2015.<\/span>\uff09<\/span><\/span><\/p>\n

\u5728<\/span>AKT<\/span>\u6291\u5236\u5242<\/span>ipatasertib<\/span>\u52a0<\/span>paclitaxel<\/span>\u7528\u4e8e\u4e09\u9634\u4e73\u817a\u764c\u7684<\/span>II<\/span>\u671f\u8bd5\u9a8c<\/span>LOTUS<\/span>\u4e2d\uff0c<\/span>Roche<\/span>\u5e94\u7528<\/span>FoundationOne<\/span><\/em> NGS<\/span>\u5e73\u53f0\u68c0\u6d4b\u4e00\u4e2a\u7279\u6b8a\u7684\u751f\u7269\u6807\u8bb0\u7269\u2014\u2014\u53d8\u5f02\u7684<\/span>PI3KCA\/AKT1\/PTEN<\/span>\uff0c\u8fd9\u4e00\u5e94\u7528\u5bf9\u4e8e<\/span>PFS<\/span>\u7684\u98ce\u9669\u6bd4\uff08<\/span>hazardratio<\/span>\uff09\u6709\u660e\u663e\u5e2e\u52a9\u3002<\/span>(<\/span>\u8bf7\u67e5\u770b<\/span>“<\/span><\/span>Roche PushesThe Boundaries Of Cancer Immunotherapy<\/span>” -Scrip, 8 Jun, 2017.)<\/span><\/p>\n

O\u2019Day<\/span>\u8bf4\uff1a\u201c<\/span>Foundation Medicine<\/span>\u7684\u8bca\u65ad\u5206\u6790\u5bf9\u4e8e\u53d1\u73b0<\/span>ipatasertib<\/span>\u7684\u5408\u9002\u8def\u5f84\u975e\u5e38\u6709\u5e2e\u52a9\u3002\u627e\u51fa<\/span>PI3<\/span>\u3001<\/span>AKT<\/span>\u3001<\/span>PTEN<\/span>\u7684\u591a\u6837\u6027\uff0c\u5e2e\u52a9\u6211\u4eec\u56de\u987e\u4e34\u5e8a\u6570\u636e\uff0c\u5bf9\u8fd9\u4e9b\u75c5\u4eba\u8fdb\u884c\u4e9a\u7ec4\u5206\u578b\uff0c\u5206\u6790\u98ce\u9669\u6bd4\u3002\u201d<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u8ba4\u4e3a<\/span>ipatasertib<\/span>\u7684\u5546\u4e1a\u5316\u6210\u529f\u662f\u5efa\u7acb\u5728<\/span>NGS<\/span>\u53d1\u73b0\u4e86\u5408\u9002\u7684\u60a3\u8005\u7684\u57fa\u7840\u4e0a\u7684\u3002<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u8fdb\u4e00\u6b65\u8865\u5145\u9053\uff1a<\/span>Foundation Medicine<\/span>\u7684\u65b9\u6cd5\u4e5f\u5e2e\u52a9\u660e\u786e\u4e86<\/span>ipatasertib<\/span>\u7684\u9002\u5e94\u75c7\u62d3\u5c55\u65b9\u5411\uff0c\u201c\u6211\u4eec\u53ef\u4ee5\u5c06\u9002\u5e94\u75c7\u62d3\u5c55\u81f3<\/span>HER2<\/span>\u9634\u6027\u8377\u5c14\u8499\u53d7\u4f53\u9633\u6027\u7684\u60a3\u8005\uff0c\u8fd9\u6216\u8bb8\u662f\u6211\u4eec\u540e\u7eed\u52aa\u529b\u7684\u6f5c\u5728\u65b9\u5411\u3002\u201d<\/span><\/span><\/p>\n

\u7f57\u6c0f\u7684\u957f\u671f\u201c\u5168\u9762\u8bca\u65ad\u201d\uff08<\/span> comprehensive diagnostics<\/span>\uff09\u6218\u7565\uff0c\u901a\u8fc7\u65e5\u5e38\u5e7f\u6cdb\u5e94\u7528<\/span>Foundation<\/span>\u7684<\/span>NGS<\/span>\u4e0e\u7f57\u6c0f\u5df2\u7ecf\u5efa\u7acb\u7684\u514d\u75ab\u7ec4\u5316\u8bca\u65ad\u65b9\u6cd5\uff0c\u4e3a\u7f57\u6c0f\u8fd0\u7528\u65b0\u578b\u7684\u5206\u6790\u5de5\u5177\u63d0\u4f9b\u4e86\u4e00\u4e2a\u5f88\u5927\u7684\u5e93\uff0c\u5305\u62ec\u5927\u91cf\u7684\u8840\u6db2\u4e0e\u7ec4\u7ec7\u6837\u672c\u3002\u9664\u4e86\u6307\u5bfc\u7814\u53d1\u5de5\u4f5c\u5916\uff0c\u8fd9\u4e2a\u5e93\u8fd8\u53ef\u4ee5\u652f\u6301\u56de\u987e\u6027\u7504\u522b\u7684\u75c5\u4eba\u4e9a\u7ec4\u7684\u9002\u5e94\u75c7\uff0c\u800c\u907f\u514d\u4e86\u56de\u987e\u6027\u6837\u672c\u7684\u9677\u9631\uff0c\u6216\u8005\u51cf\u5c11\u4e86\u5f00\u5c55\u524d\u77bb\u6027\u8bd5\u9a8c\u7684\u5fc5\u8981\u6027\u3002<\/span><\/span><\/p>\n

\u589e\u52a0\u76d1\u7ba1\u7684\u53ef\u80fd\u6027<\/span><\/strong><\/span><\/h2>\n

Roche<\/span>\u5df2\u7ecf\u5728\u5e94\u7528<\/span>Flatiron<\/span>\u7684\u7814\u7a76\u6807\u51c6\u7684\u7535\u5b50\u533b\u7597\u8bb0\u5f55\u6570\u636e\u5e93\u6765\u521b\u9020\u865a\u62df\u7684\u63a7\u5236\u81c2\uff08<\/span>control arm<\/span>\uff09\uff0c\u8fd9\u4e2a\u5e93\u76ee\u524d\u5df2\u7ecf\u5305\u542b\u4e86<\/span>1000<\/span>\u4e07\u60a3\u8005\u3002<\/span>O\u2019Day<\/span>\u8bf4\uff1a\u201c\u8fd9\u662f\u4e00\u79cd\u771f\u6b63\u80fd\u591f\u6df1\u5ea6\u8fdb\u5165\u6570\u636e\u5e93\u4e0e\u57fa\u56e0\u7ec4\u5b66\u7684\u529b\u91cf\uff0c\u901a\u8fc7<\/span>Flatiron<\/span>\uff0c\u6211\u4eec\u5df2\u7ecf\u83b7\u5f97\u4e86\u4e00\u7cfb\u5217\u4e0d\u540c\u7684\u6210\u529f\u6848\u4f8b\u3002\u201d<\/span><\/span><\/p>\n

\u5916\u90e8\u7684\u6216\u8005\u5386\u53f2\u7684\u63a7\u5236\u81c2\u662f<\/span>FDA<\/span>\u8bc4\u4ef7\u7597\u6548\u7684\u9996\u8981<\/span>RWE<\/span>\u6807\u51c6\uff0c\u4f46\u662f\u4e8b\u5b9e\u4e0a\u57fa\u4e8e\u8fd9\u7c7b\u6807\u51c6\u7684\u5ba1\u6279\u5c11\u4e4b\u53c8\u5c11\uff0c\u5f80\u5f80\u96c6\u4e2d\u5728\u6781\u5ea6\u7a00\u5c11\u7684\u5b64\u513f\u836f\u9886\u57df\u3002\u800c\u7f57\u6c0f\u5927\u89c4\u6a21\u5e94\u7528\u6570\u5b57\u6280\u672f\u5219\u63d0\u4f9b\u4e86\u53e6\u5916\u7684\u53ef\u80fd\u6027\u3002<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u8bc4\u8bba\u8bf4\uff1a\u201c\u6211\u4eec\u76ee\u524d\u5df2\u7ecf\u5728<\/span>10<\/span>\u4e2a\u8bd5\u9a8c\u4e0a\u91c7\u7528\u4e86\u8fd9\u4e9b\u6280\u672f\u3002\u201d\u4ed6\u6307\u51fa<\/span>Roche<\/span>\u5728<\/span>Tecentriq<\/span>\u7528\u4e8e<\/span>2<\/span>\u7ebf<\/span>NSCLC<\/span>\u7684\u540d\u4e3a<\/span>OAK<\/span>\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u7684\u5916\u90e8\u63a7\u5236\u81c2\u4e0a\uff0c\u5c31\u4f7f\u7528\u4e86\u771f\u5b9e\u4e16\u754c\u6570\u636e\u3002\u7814\u7a76\u4eba\u5458\u5728<\/span>Flatiron<\/span>\u7535\u5b50\u533b\u7597\u8bb0\u5f55\u6570\u636e\u5e93\u4e2d\uff0c\u5229\u7528\u771f\u5b9e\u7684<\/span>OAK<\/span>\u8bd5\u9a8c\u7684\u63a7\u5236\u81c2\u7684\u7279\u6027\uff0c\u56de\u987e\u6027\u7684\u91cd\u5efa\u4e86<\/span>docetaxel<\/span>\u63a7\u5236\u81c2\u3002<\/span>O\u2019Day<\/span>\u8bf4\uff1a\u201c\u6211\u4eec\u80fd\u591f\u4ece\u7edf\u8ba1\u5b66\u7684\u89d2\u5ea6\u6a21\u62df\u63a7\u5236\u81c2\u7684\u6d3b\u52a8\u3002\u201d<\/span><\/span><\/p>\n

\u4ed6\u6307\u51fa\uff1a\u5176\u4ed6\u6709\u516c\u53f8\u4e5f\u5728\u4f7f\u7528<\/span>Flatiron<\/span>\u7684\u6570\u636e\u5f00\u5c55\u76f8\u5173\u5de5\u4f5c\u3002\u6b64\u5916\uff0c<\/span>Flatiron<\/span>\u4e5f\u5728\u4e0e<\/span>FDA<\/span>\u7684\u4e00\u4e2a\u540d\u4e3a<\/span>INFORMED<\/span>\u7684\u5408\u4f5c\u76d1\u7ba1\u79d1\u5b66\u5b75\u5316\u5668\u5408\u4f5c\uff0c\u5728\u4e00\u9879\u793a\u8303\u6027\u9879\u76ee\u4e2d\u5ba1\u67e5<\/span>NSCLC<\/span>\u7684\u514d\u75ab\u7597\u6cd5\u7684<\/span>RWE<\/span>\u3002<\/span><\/span><\/p>\n

\u4ed6\u63d0\u5230\uff1a\u201c\u6211\u8ba4\u4e3a\u8fd9\u4e2a\u5e94\u7528\u975e\u5e38\u6709\u6f5c\u529b\uff0c\u53ef\u4ee5\u5e2e\u52a9\u6211\u4eec\u5ba1\u89c6\u672a\u6765\u5982\u4f55\u5f00\u5c55\u4e34\u5e8a\u8bd5\u9a8c\u3002\u201d<\/span><\/p>\n

O\u2019Day<\/span>\u5bf9\u4e8e\u8ba9\u76d1\u7ba1\u673a\u6784\u63a5\u53d7\u8fd9\u7c7b\u6570\u636e\u6301\u4e50\u89c2\u6001\u5ea6\u3002\u4ed6\u6307\u51fa\u7f8e\u56fd<\/span>FDA<\/span>\u8d1f\u8d23\u4eba<\/span>Scott Gottlieb<\/span>\u8868\u793a\u201c\u9ad8\u5ea6\u9f13\u52b1\u9ad8\u8d28\u91cf\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\uff0c\u5982\u679c\u8fd9\u7c7b\u6570\u636e\u80fd\u591f\u5e2e\u52a9\u4e34\u5e8a\u8bd5\u9a8c\u4ece\u76d1\u7ba1\u7684\u89d2\u5ea6\u5b9e\u73b0\u5dee\u5f02\u5316\uff0c\u5e2e\u52a9\u6211\u4eec\u52a0\u901f\u836f\u54c1\u4e0a\u5e02\u7684\u8bdd\u3002\u201d<\/span><\/span><\/p>\n

\u6709\u4eba\u5728<\/span>ASCO<\/span>\u4f1a\u8bae\u4e0a\u95ee<\/span>Roche<\/span>\u7528\u65b0\u65b9\u6cd5\u66ff\u4ee3\u4f20\u7edf\u4e34\u5e8a\u8bd5\u9a8c\u7684\u7f3a\u70b9\uff0c\u6bd5\u7adf\u4e34\u5e8a\u8bd5\u9a8c\u88ab\u8ba4\u4e3a\u662f\u6536\u96c6\u8bc1\u636e\u7684\u91d1\u6807\u51c6\uff0c\u800c\u4e14\u901a\u8fc7\u64cd\u4f5c\u6570\u636e\uff0c\u7f57\u6c0f\u53ef\u4ee5\u4ea7\u751f\u4ed6\u4eec\u5e0c\u671b\u7684\u6570\u636e\uff0c\u800c\u907f\u514d\u4e86\u5934\u5bf9\u5934\u8bd5\u9a8c\u7684\u6f5c\u5728\u98ce\u9669\u3002<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u5bf9\u6b64\u627f\u8ba4\u786e\u5b9e\u6709\u8fc7\u4f4e\u8bbe\u7f6e\u6807\u51c6\u7684\u98ce\u9669\uff0c\u800c\u8fc7\u4f4e\u8bbe\u7f6e\u6807\u51c6\u5219\u53ef\u80fd\u5bfc\u81f4\u201c\u6211\u4eec\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u6e90\u5411\u6211\u4eec\u63d0\u4f9b\u4e86\u4e0d\u51c6\u786e\u7684\u4fe1\u606f\u201d\u3002<\/span>Roche<\/span>\u51b3\u5b9a\u6536\u8d2d<\/span>Flatiron<\/span>\u662f\u56e0\u4e3a\u7f57\u6c0f\u8ba4\u4e3a\u8be5\u516c\u53f8\u786e\u5b9e\u83b7\u5f97\u4e86\u7b26\u5408\u76d1\u7ba1\u7ea7\u522b\u7684\u6570\u636e\u3002\u4ed6\u8bf4\u9053\uff1a\u201c\u5176\u4ed6\u7684\u6570\u636e\u6e90\u6216\u8bb8\u8fd8\u6ca1\u6709\u8fbe\u5230\u8fd9\u4e2a\u6807\u51c6\uff0c\u8fd9\u662f\u4ed6\u4eec\u9047\u5230\u7684\u95ee\u9898\u3002\u201d<\/span><\/span><\/p>\n

Alan Sandler<\/span>\u662f\u7f57\u6c0f\u5168\u7403\u80ba\u764c\u7ba1\u7ebf\u8d1f\u8d23\u4eba\uff0c\u4ed6\u6307\u51fa<\/span>Roche<\/span>\u7684\u771f\u5b9e\u4e16\u754c\u6570\u636e\u6218\u7565\u5728\u8bc4\u4f30\u6f5c\u5728\u7ec4\u5408\u7597\u6cd5\u7684\u4f18\u52bf\uff1a\u53ef\u4ee5\u7528\u5408\u9002\u7684\u771f\u5b9e\u4e16\u754c\u539f\u59cb\u6570\u636e\u6765\u6d4b\u8bd5\u5404\u79cd\u5047\u8bf4\uff0c\u800c\u4e0d\u9700\u8981\u901a\u8fc7\u4e34\u5e8a\u8bd5\u9a8c\u3002\u8fd9\u6837\u53ef\u4ee5\u5e2e\u52a9\u7f57\u6c0f\u8bc4\u4f30\u5404\u79cd\u8054\u5408\u7528\u836f\u7684\u53ef\u80fd\u6027\uff0c\u5145\u5206\u53d1\u6325\u81ea\u5df1\u4ea7\u54c1\u7684\u6f5c\u80fd\uff0c\u800c\u4e0d\u5fc5\u5f00\u5c55\u771f\u5b9e\u7684\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/span><\/span><\/p>\n

\u51c6\u5907\u597d\u8fce\u63a5\u672a\u6765<\/span><\/strong><\/span><\/h2>\n

\u8fd9\u5bb6\u745e\u58eb\u80bf\u7624\u884c\u5bb6\u5728<\/span>ASCO<\/span>\u4e0a\u4e5f\u63d0\u5230\u4e86\u5927\u91cf\u4e0e\u5176\u4ed6\u516c\u53f8\u7c7b\u4f3c\u7684\u8bdd\u9898\uff0c\u6bd4\u5982\u5982\u4f55\u63a8\u8fdb\u5b83\u7684<\/span>IO<\/span>\u7ba1\u7ebf\uff0c\u5c55\u793a<\/span>Tecentriq<\/span>\u5728\u67d0\u4e9b\u4e9a\u7ec4\u7684\u6570\u636e\uff0c\u8054\u5408\u7528\u836f\u7684\u53ef\u80fd\u6027\uff0c\u4ee5\u53ca\u5b83\u5728\u591a\u4e2a\u9002\u5e94\u75c7\u7684\u5e94\u7528\u3002<\/span><\/span><\/p>\n

\u7ee7\u7eed\u63a8\u52a8\u8fd9\u4e9b\u4e8b\u60c5\u80fd\u591f\u5e2e\u52a9<\/span>Roche<\/span>\u5728\u77ed\u65f6\u95f4\u5185\u5728\u80bf\u7624\u9886\u57df\u4fdd\u6301\u5728\u884c\u4e1a\u524d\u5217\uff0c\u5c3d\u7ba1\u8be5\u516c\u53f8\u9762\u4e34\u4e00\u7cfb\u5217\u5a01\u80c1\uff0c\u6bd4\u5982<\/span>Avastin <\/span><\/em>(bevacizumab) <\/span>\u548c<\/span> Herceptin<\/span><\/em>(trastuzumab)<\/span>\u5373\u5c06\u9762\u4e34\u7684\u751f\u7269\u7c7b\u4f3c\u836f\u7684\u5a01\u80c1\u3001<\/span>PI3<\/span>\u6fc0\u9176\u6291\u5236\u5242\u4ee4\u4eba\u5931\u671b\u7684\u4e34\u5e8a\u6570\u636e\u3002<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u5f3a\u8c03\uff1a\u201c<\/span>Roche<\/span>\u7684\u521b\u65b0\u6218\u7565\u4f9d\u7136\u6ca1\u6709\u53d1\u751f\u6539\u53d8\u3002\u201d\u4f46\u662f\u73b0\u5728\u6218\u7565\u7684\u4e2d\u5fc3\u5df2\u7ecf\u53d8\u6210\u4e86\u6570\u636e\u4e0e\u9ad8\u7ea7\u5206\u6790\uff0c\u8fd9\u53ef\u4ee5\u5e2e\u52a9\u5230\u5728\u7814\u7ba1\u7ebf\u4e0e\u4e0a\u5e02\u836f\u7269\uff0c\u5e2e\u52a9\u516c\u53f8\u5728\u901f\u7387\u3001\u7a33\u5b9a\u6027\u3001\u7075\u6d3b\u6027\u4e0a\u8f6c\u578b\u3002<\/span><\/span><\/p>\n

O\u2019Day<\/span>\u8bf4\uff1a\u201c\u8fd9\u5bf9\u6211\u4eec\u6240\u6709\u7684\u4e1a\u52a1\u90fd\u4f1a\u6709\u5370\u8c61\u3002\u81f3\u5c11\u5bf9\u4e8e<\/span>Roche<\/span>\u4ee5\u53ca<\/span>Genetech<\/span>\u800c\u8a00\uff0c\u8fd9\u7edd\u5bf9\u5904\u4e8e\u6211\u4eec\u6218\u7565\u7684\u6838\u5fc3\u90e8\u4f4d\u3002\u201d<\/span><\/span><\/p>\n

\u4ed6\u8865\u5145\u9053\uff1a\u201c\u5bf9\u6211\u4eec\u800c\u8a00\uff0c\u6700\u91cd\u8981\u7684\u5f52\u6839\u5230\u5e95\u8fd8\u662f\u6211\u4eec\u5c06\u7ee7\u7eed\u53d1\u73b0\u4e0e\u5f00\u53d1\u836f\u7269\uff0c\u5e76\u628a\u5b83\u4eec\u5e26\u7ed9\u60a3\u8005\u3002\u4f46\u662f\u6211\u4eec\u80fd\u591f\u8ba9\u81ea\u5df1\u7684\u5de5\u4f5c\u66f4\u52a0\u806a\u660e\u3001\u5feb\u901f\u3001\u4f18\u5316\u3002\u5728\u836f\u7269\u7814\u53d1\u4ef7\u503c\u66f2\u7ebf\u7684\u5404\u4e2a\u9636\u6bb5\uff0c\u4ece\u65e9\u671f\u5230\u665a\u671f\uff0c\u8fd9\u90fd\u80fd\u5e2e\u52a9\u6211\u4eec\u63d0\u5347\u6211\u4eec\u7684\u4ea7\u51fa\u3002\u201d<\/span><\/p>\n

\u672c\u6587\u8f6c\u8f7d\u81eaInforma\u751f\u547d\u79d1\u5b66\u667a\u5e93 \u3002<\/span><\/span><\/p>\n

<\/span><\/p>\n

\n

\u6392\u7248\uff1a\u6885\u5e0c<\/span><\/p>\n

\n
\n
\n
<\/span>\u5e7f\u800c\u544a\u4e4b<\/span><\/section>\n<\/section>\n<\/section>\n
\n
\n

\u2299 \u540c\u5199\u610f\u57f9\u8bad<\/span><\/p>\n

\u5199\u610f\u8bba\u575b\u4e28\u5c0f\u5206\u5b50\u521b\u65b0\u836f\u7269\u53d1\u73b0\uff08\u9644180\u4f4d\u53c2\u4f1a\u8005\u4fe1\u606f\uff09<\/span><\/a>
<\/p>\n

\u5c0f\u5206\u5b50\u521b\u65b0\u836f\u7269\u53d1\u73b0\u2014\u2014\u7406\u8bba\u3001\u5b9e\u8df5\u3001\u8fc7\u7a0b\u4e0e\u5c55\u671b<\/a><\/span>
<\/p>\n

\u5199\u610f\u8bba\u575b\u4e28\u65b0\u836f\u4e2d\u7f8e\u53cc\u62a5\u4e4b\u5236\u5242\u6eb6\u51fa\u6280\u672f\u5f00\u53d1<\/a><\/span><\/p>\n

\u5199\u610f\u8bba\u575b\u4e28\u56fd\u9645\u89c4\u8303\u4e0b\u751f\u7269\u836f\u5168\u751f\u547d\u5468\u671f\u8d28\u91cf\u7ba1\u7406<\/span><\/a><\/p>\n<\/section>\n

\n

\u2299 \u57f9\u4f18\u57f9\u8bad<\/span><\/p>\n

\u4f1a\u8baf|\u6539\u826f\u578b\u521b\u65b0\/505(b)(2)\u7acb\u9879\u7814\u53d1\u66a8\u4e2d\u7f8e\u53cc\u62a5\u7814\u8ba8\u4f1a\u9080\u8bf7\u51fd<\/a><\/span><\/p>\n


<\/section>\n<\/section>\n<\/section>\n


<\/p>\n

\n

\"\u65b0\u4e00\u4ee3\u7684\u7f57\u6c0f\uff1a\u6570\u636e\u5206\u6790\u5982\u4f55\u8ba9\u5b83\u4fdd\u6301\u80bf\u7624\u9886\u57df\u7684\u9886\u5148\u5730\u4f4d\"
<\/p>\n

\u836f\u4e8b\u7eb5\u6a2a\u662f\u4e00\u4e2a\u5f00\u653e\uff0c\u7531\u81ea\u613f\u8005\u7ec4\u6210\u7684\u56e2\u4f53\uff0c\u73b0\u6709\u6210\u545838\u540d\uff0c\u5206\u522b\u4e3aVoyager88\uff08\u9b4f\u5229\u519b\uff09\uff0c\u96f7\u8bfa\u5c9b\uff0c\u4e09\u5206\u8bdd\uff0cHerman\uff0c\u6885\u5e0c\uff0c\u6587\u7af9\uff0cduke\uff0cyhqqqqq\uff0c\u5360\u5c0f\u5175\uff0c\u98ce\u4e00\u6837\u7684\u5c4e\u58f3\u90ce\uff0c\u9526\u5fc3\u7ee3\u53e3\uff0cflydp511\uff0c\u5de7\u5de7\uff0c\u4e91\u6c34\u9053\u4eba\uff0c\u9621\u4e0a\u964c\u964c\uff0c\u591a\u5df4\u80fa\uff0c\u745c\u513f\uff0cKailyn\uff0cSmall fish\uff0c\u5b50\u708e\uff0c\u514b\u683c\u83ab\uff0cVicky\uff0cPandada\uff0c\u83ab\u5306\u5306\uff0cSophia\uff0c\u4f9d\u7136\u7279\u96f7\u897f\uff0c\u5076\u9635\u96e8\uff0cAimee\uff0c\u4ed6\u5c71\u4e4b\u77f3\uff0c\u5510\u5c0f\u7396\uff0c\u96f6\u4e0b274\u2103\uff0cGloria\uff0cBreathless\uff0cLuffy\uff0c\u80e1\u4e0d\u559c\uff0c Helen\uff0c\u843d\u843d\uff0cSUNRISE\u3002\u6b22\u8fce\u6709\u5fd7\u4e4b\u58eb\u52a0\u5165\u6211\u4eec\u56e2\u961f\u3002\u6295\u7a3f\u3001\u5408\u4f5c\u3001\u52a0\u4e13\u4e1a\u7fa4\u8bf7\u52a0\u5fae\u4fe1442015666\uff0c\u836f\u4e8b\u7eb5\u6a2a\u4e8c\u5343\u4ebaQQ\u7fa422711855\u3002<\/p>\n

\n

\u59cb\u53d1\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7\uff1a \u836f\u4e8b\u7eb5\u6a2a <\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u6982\u89c8 Roche\u5728\u672c\u5c4aASCO\u4e0a\u91cd\u70b9\u9610\u8ff0\u4e86\u81ea\u5df1\u7684\u6570\u5b57\u5316\u4e0e\u4e2a\u6027\u5316\u5065\u5eb7\u6218\u7565\uff0c\u5e76\u4e3e\u4f8b\u8bf4\u660e\u4e86\u65b0\u7684\u6218\u7565\u5982\u4f55\u8ba9\u81ea\u5df1\u4fdd\u6301\u5728\u80bf […]<\/p>\n","protected":false},"author":1,"featured_media":20215,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/20214"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=20214"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/20214\/revisions"}],"predecessor-version":[{"id":20221,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/20214\/revisions\/20221"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/20215"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=20214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=20214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=20214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}